What is the current stock price of Pressure BioSciences, Inc. (PBIO)?

As of the latest market data, Pressure BioSciences, Inc. (PBIO) is trading at $0.00. The stock has seen a loss of 0.00% today.

Does Pressure BioSciences, Inc. (PBIO) pay a dividend?

Based on current data, Pressure BioSciences, Inc. does not have a confirmed active dividend policy.

What is the market cap of Pressure BioSciences, Inc.?

The current market capitalization of Pressure BioSciences, Inc. (PBIO) is approximately unavailable.

PBIO

Pressure BioSciences, Inc.·Healthcare

0.00

0.000%(+0.00)

Market Closed

Last Updated: — ET

52W L: $0.0052W H: $0.20

PBIO NEWS

defenseworld.net

5d ago

Head-To-Head Comparison: Pressure BioSciences (OTCMKTS:PBIO) and Artivion (NYSE:AORT)

Pressure BioSciences (OTCMKTS:PBIO - Get Free Report) and Artivion (NYSE: AORT - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, profitability, analyst recommendations, risk and valuation. Earnings and Valuation This table compares Pressure BioSciences

defenseworld.net

Apr 2

Head-To-Head Review: Positron (OTCMKTS:POSC) versus Pressure BioSciences (OTCMKTS:PBIO)

Institutional and Insider Ownership 0.0% of Pressure BioSciences shares are owned by institutional investors. 10.8% of Pressure BioSciences shares are owned by company insiders. Comparatively, 17.2% of Positron shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term

defenseworld.net

Mar 2

Reviewing Pressure BioSciences (OTCMKTS:PBIO) & enVVeno Medical (NASDAQ:NVNO)

Pressure BioSciences (OTCMKTS:PBIO - Get Free Report) and enVVeno Medical (NASDAQ: NVNO - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk. Analyst Ratings This is a summary of

Company Profile

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts. As of August 2, 2022, Pressure BioSciences, Inc. operates as a subsidiary of Emergent Health Corp.

Sector

Healthcare

Industry

Medical - Devices

Employees

IPO Date

1996-10-31

Beta

-0.80

Websitewww.pressurebiosciences.com↗